Loading...
The Indonesia Syringe market is forecast to grow at a CAGR of 5.6%, reaching USD 305.8 million in 2031 from USD 232.8 million in 2026.
The Indonesian syringe market is estimated to grow steadily during the forecast period. A key factor driving the market forward is the increasing local production in the healthcare sector nationwide. Furthermore, growing governmental investments to develop the nation’s healthcare infrastructure will also ensure growth. With the growth in patient numbers and increasing healthcare access further driving the patient number, the demand for Indonesia’s syringe market is significantly growing.
During the forecast period, the market will experience a significant shift towards prefilled syringes as they are seen as safer and more convenient. Additionally, there is a growing trend towards Auto-Disable (AD) syringes and smart syringes, driven by government regulations as well as growing consumer awareness. The market is experiencing significant growth in both production capacity and export volume.
| Report Metric | Details |
|---|---|
| Total Market Size in 2025 | USD 220.495 million |
| Total Market Size in 2030 | USD 290.446 million |
| Forecast Unit | Million |
| Growth Rate | 5.67% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Type, Material, Syringe Size |
| Companies |
|
A syringe is a glass or plastic tube containing a needle on one side. It is used to deliver the drug to the veins of the body or to take small samples of blood for medical tests and procedures. A syringe is among the most important types of medical devices, which helps medical professionals. It has multiple benefits, like the elimination of dose errors, and offers easy application and administration of medicines.
Indonesia is benefiting from greater purchasing power and improved exposure to healthcare facilities as the country's economic situation improves. The government has substantially enhanced expenditures on health care and programs supported by medicine for Indonesia's poor households. The lifestyle and dietary habits of Indonesians are changing as a result of the country's improving economic situation. This aggravates lifestyle-related health conditions like high blood pressure and hypertension. As a result, the demand for medicines and the medical equipment needed to administer them, such as syringes, has surged in Indonesia in recent years, supporting the country's syringe industry.
The rapid increase in the nation’s older population is among the major factors boosting the demand for syringes in the market. With the ageing population, the risk of diseases also increases, pushing the need for medical care among the older population. Various diseases, like cancer, diabetes, respiratory diseases, and heart diseases, are common among people aged 65. For such diseases, the syringe plays a critical role in efficient and optimal medicine management. In diabetes, a syringe helps to accurately deliver insulin to the body, with proper dose management. According to the data by the World Bank, the percentage of the population aged 65 and above grew from 6% in 2014 to 7% in 2024. Additionally, the growth in the overall population in Indonesia (expected to reach 286.1 million by the end of 2025) is also driving the market.
Another major factor boosting Indonesia's syringe market is the nation's growing healthcare sector. The nation witnessed massive growth in its healthcare industry development, mainly with the increasing investments by the government and private organizations in developing the local pharmaceutical sector manufacturing. As per the World Bank, by 2024, the national health insurance scheme, Jaminan Kesehatan Nasional cover over 79% of the population, enhancing financial protection and health services, driving the healthcare access to the market.
The International Trade Administration, in its 2024 report, stated that in 2021, the nation's healthcare market size was estimated at US$3,386 million, with about US$2,331 million in local healthcare production. The local production of healthcare increased to 2,564 million in 2022, which further rose to about US$2,808 million in 2023.
Furthermore, Indonesia has partnered with the World Bank (US$1.5 billion), Asian Infrastructure Investment Bank (US$1 billion) and Asian Development Bank (US$650 million) as joint co-financiers, and Islamic Development Bank (US$846 million) through parallel financing to support its health transformation agenda through the Health System Strengthening (HSS) Project.
The market is moderately fragmented, featuring a mix of local manufacturers such as PT Oneject and multinational medical device firms such as B. Braun, BD, Terumo, Nipro, ICU Medical, and ILS. There is a strong base of local manufacturers, while the multinational companies also have a broad product portfolio, global QA, regulatory approvals, and stronger relationships with large hospital groups, holding a key market share. Some of the major companies are PT. Becton Dickinson Indonesia, PT Oneject Indonesia (TDC Indonesia), and PT. Nipro Indonesia Jaya, among others. For example, PT. Becton Dickinson Indonesia is an Indonesian subsidiary of Becton Dickinson, a global medical technology provider. The company offers solutions like clinicians, administrators, drug development, laboratories, and pharmacies, among others. Another company, PT. Oneject Indonesia, is among the biggest manufacturers of medical devices in the nation. The company offers a wide range of products and services, and is among the pioneers of AD syringe manufacturers. There are many other local manufacturers, also like the PT. Nipro Indonesia Jaya. It is an Indonesian subsidiary of the Japanese healthcare corporation, Nipro. The company offers a wide range of products and services, like diabetes care, general hospital supplies, home infusion therapy, and infection control, among others.
Growing Adult Population in the Nation: The rapid increase in the nation’s older population is among the major factors boosting the demand for syringes in the market. With the aging population, the risk of diseases also increases, pushing the need for medical care among the older population. Various diseases, like cancer, diabetes, respiratory diseases, and heart diseases, are common among people aged above 65. For such diseases, the syringe plays a critical role in efficient and optimal medicine management. In diabetes, a syringe helps to accurately deliver insulin to the body, with proper dose management.
The World Bank, in its report, stated that Indonesia witnessed a massive growth in its aging population. The organization noted that in 2021, the total population above the age of 65 years was recorded at 18.559 million, which increased to 18.891 million in 2022 and 19.459 million in 2023.
The number of adults is increasing, and along with it, we are seeing an increase in chronic diseases associated with aging, including diabetes, hypertension, cardiovascular illnesses, arthritis, and cancer. Indonesia has the fifth-highest number of adults (20-79 years) with diabetes in the world. The country has 20.4 million cases as of 2024, according to the International Diabetes Federation (IDF).
Furthermore, the rise in the number of adults is another reason leading to the increased number of hospital visits, operations, and diagnostic testing. These medical activities involve the use of syringes, which consumers use for blood collection, the administration of anesthesia, and other therapeutic injections. As most adults move into higher age groups, healthcare providers are experiencing more patient visits, increasing the use of syringes.
Extensive Healthcare Industry: The extensive healthcare industry and the rising number of hospitals in the country are expected to help the Indonesian syringe market. The number of hospitals in the country has grown and is anticipated to grow even more throughout the projected period as a result of the need to expand the capacity of healthcare facilities, as well as the significant growth in healthcare spending and optimistic economic outlook following the COVID-19 pandemic. The Indonesian government announced investments as part of the law for medical device suppliers, hospitals, pharmaceutical wholesalers, and pharmaceutical manufacturers. The Indonesian syringe market, thus, has benefited tremendously from the extension of the healthcare industry, as increased healthcare infrastructure will allow more patients to have their treatment, causing an increase in demand for syringes for medical procedures.
Limitation of Healthcare Access: The limitation of the healthcare sector to a major chunk of Indonesians is acting as a restraint for market expansion. As a substitute for the medical and healthcare services provided in hospitals, Indonesians believe in and employ a variety of traditional medical treatments and medications. Even though a large number of people are eligible for the program, access to modern healthcare is still limited for a variety of reasons, such as a lack of hospitals and clinics, a lack of knowledge, and lengthy and complicated bureaucracies for those who receive government-sponsored healthcare services. As a result, this hinders the expansion of the Indonesian syringe market.
By Syringe Type: Insulin Syringe
The Indonesian syringe market is segmented into Insulin syringes and Conventional syringes based on the type of syringe. Indonesia is classified as one of the major countries experiencing health issues due to lifestyle changes, urbanization, and an aging population. The diagnoses for both types of diabetes have been growing enormously, ranking among the top countries in the world concerning this condition, affecting millions. Trends related to the rise of obesity, unhealthy diets, and a sedentary lifestyle contribute to the increase in diabetes in the country. Additionally, the nation’s medical infrastructure is growing, and with more people becoming aware of the disease, the demand for insulin syringes will grow in the coming years.
The market for insulin syringes will grow in the projected period as the number of people suffering from diabetes is expected to grow in the coming years. For instance, according to the International Diabetes Federation (IDF), in 2021, 19,465.1 people in 1,000 aged from 20 to 79 were suffering from diabetes; this is expected to grow to 28,569.9 people in 1,000 in 2045. Hence, the increasing number of people suffering from diabetes is propelling the demand for insulin syringes in the projected period.
Moreover, the recent product launches in the Indonesian insulin syringe market will also fuel the demand for this segment in the coming years. For instance, in December 2022, Gan & Lee Pharmaceuticals Co., Ltd. partnered with an Indonesian pharmaceutical company on locally filled insulin glargine, prefilled pens, and insulin aspart 5 prefilled pens for great results. Hence, such product launches are fuelling the market for insulin syringes during the projected period.
September 2024 - BD Neopak™ XtraFlow™ Glass Prefillable Syringe: In September 2024, BD (Becton, Dickinson and Company), a leading global medical technology company, announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak™ Glass Prefillable Syringe platform to serve the growing market for biologic therapies. The BD Neopak™ Glass Prefillable Syringe platform will address the needs for biological drugs for more than 24 indications, including Crohn's disease, atopic dermatitis, cardiovascular disease, and various rare diseases. The BD Neopak™ XtraFlow™ Glass Prefillable features an 8-millimetre needle length and a thinner wall cannula to optimize subcutaneous delivery of higher viscosity drug profiles by reducing the injection force and time required for a fixed solution viscosity.
October 2024 - SK Bioscience SKYCellflu Vaccine: In October 2024, SK Bioscience, a global innovative vaccine and biotech company, received approval for its quadrivalent cell-cultured influenza vaccine, SKYCellflu, from Indonesia's Food and Drug Agency (BPOM). This is a significant milestone as, for the first time, a domestically developed influenza vaccine has been licensed in Indonesia.